Trial Profile
evaluation of aloGliptin`s eFficacy and saFety based on Renal function Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms eGFR
- 25 May 2012 Planned End Date added to 1 Dec 2015 as reported by University Hospital Medical Information Network - Japan.
- 24 Aug 2011 New trial record